These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9723300)

  • 21. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation.
    Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA
    Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral.
    Levy GA
    Transplant Proc; 1996 Aug; 28(4):2252-3. PubMed ID: 8769216
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical impact of Neoral in heart transplantation.
    Aziz T; el-Gamel A; Keevil B; Martyszczuk R; Campbell C; Rahman A; Deiraniya A; Yonan N
    Transplant Proc; 1998 Jun; 30(4):1152-3. PubMed ID: 9636466
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of nicardipine on blood cyclosporine levels in renal transplant patients.
    Guan D; Wang R; Lu J; Wang M; Xu C
    Transplant Proc; 1996 Jun; 28(3):1311-2. PubMed ID: 8658673
    [No Abstract]   [Full Text] [Related]  

  • 25. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2).
    Levy G; Burra P; Cavallari A; Duvoux C; Lake J; Mayer AD; Mies S; Pollard SG; Varo E; Villamil F; Johnston A
    Transplantation; 2002 Mar; 73(6):953-9. PubMed ID: 11923699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of cyclosporine dosing on creatinine levels in hepatic transplant recipients.
    Gross CR; Savik SK; Ascher NL; Gordon RD; Klintmalm GB; Payne W; Shaw BW; Strasburg K; Parker A; Wiesner RH
    Transplant Proc; 1994 Oct; 26(5):2686-90. PubMed ID: 7940841
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety and tolerability of Neoral in transplant recipients.
    Feutren G; Wong R; Jin J; Niese D; Mellein B
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract]   [Full Text] [Related]  

  • 28. Role of cyclosporine in inducing hyperuricemia in heart transplant patients.
    Sahar G; Stamler A; Berman M; Ben Gal T; Vaturi M; Aravot D; Vidne BA
    Transplant Proc; 2000 Jun; 32(4):729-30. PubMed ID: 10856561
    [No Abstract]   [Full Text] [Related]  

  • 29. Disappearance of diabetes mellitus after conversion from FK 506 to Neoral in two liver transplanted patients.
    Lagget M; Marzano A; Actis GC; Leone N; Ciancio A; Salizzoni M; Rizzetto M
    Transplant Proc; 1998 Aug; 30(5):1863-4. PubMed ID: 9723312
    [No Abstract]   [Full Text] [Related]  

  • 30. Neoral in liver transplantation.
    Levy GA; Grant D
    Transplant Proc; 1996 Apr; 28(2):1019-21. PubMed ID: 8623216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Results of conversion from Sandimmune to Neoral in stable pediatric liver transplant recipients after two years.
    Dunn SP; Falkenstein K; Pierson A; Cooney GF
    Transplant Proc; 1998 Aug; 30(5):1962-3. PubMed ID: 9723353
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of immunosuppressive therapy in neuroendocrine activation after human heart, renal, and liver transplantation.
    Piquard F; Geny B; Elero B; Canguilhem B; Mettauer B; Epailly E; Chakfe N; Charpentier A; Wolf P; Kretz JG; Eisenmann B; Koehl C; Haberey P
    Transplant Proc; 1998 Aug; 30(5):2124-6. PubMed ID: 9723414
    [No Abstract]   [Full Text] [Related]  

  • 33. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil.
    Herrero JI; Quiroga J; Sangro B; Girala M; Gómez-Manero N; Pardo F; Alvárez-Cienfuegos J; Prieto J
    Liver Transpl Surg; 1999 Sep; 5(5):414-20. PubMed ID: 10477843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of mycophenolate mofetil in organ transplant recipients.
    Schweizer RT; Meisterling LD
    Transplant Proc; 2001 May; 33(3):2309. PubMed ID: 11377540
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience with neoral cyclosporine through the oral route in liver transplantation.
    Bilbao I; Lazaro JL; Pou L; Charco R; Hildalgo E; Murio E; Margarit C
    Transplant Proc; 1998 Jun; 30(4):1432-4. PubMed ID: 9636580
    [No Abstract]   [Full Text] [Related]  

  • 36. Monitoring of renal function in children before and after liver transplantation.
    Vajro P; Pecoraro C; De Vincenzo A; Genovese E; Silvestre C; Brancato T; Migliaro F
    Transplant Proc; 1998 Aug; 30(5):1991-2. PubMed ID: 9723364
    [No Abstract]   [Full Text] [Related]  

  • 37. Cyclosporine A is associated with a shift of the Th1/Th2 balance in liver transplant patients.
    van den Berg AP; Twilhaar WN; Corver K; Geerts AB; Mesander G; Klompmaker IJ; Slooff MJ; The TH; de Leij LH
    Transplant Proc; 1998 Aug; 30(5):2378-9. PubMed ID: 9723510
    [No Abstract]   [Full Text] [Related]  

  • 38. Single-center study utilizing C(2) level as monitoring tool in de novo renal transplant recipients treated with Neoral.
    Keshavamurthy M; Al Ahmadi I; Mohammed Raza S; Baynton R; Al Meshari K; Al Shaibani K
    Transplant Proc; 2001; 33(7-8):3112-4. PubMed ID: 11750338
    [No Abstract]   [Full Text] [Related]  

  • 39. Reduced acute rejection and side effects with neoral in liver transplantation.
    Tisone G; Vennarecci G; Pisani F; Baiocchi L; Mercadante E; Orlando G; Anselmo A; Casciani CU
    Transplant Proc; 1998 Jun; 30(4):1430-1. PubMed ID: 9636579
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma and low-density lipoprotein lipid peroxidation in cyclosporine A-treated children after liver transplant.
    Granot E; Shemesh P; Rivkin L; Kohen R
    Transplant Proc; 1998 Dec; 30(8):4057-9. PubMed ID: 9865293
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.